Nerve injury completely eliminates the ability of opioid receptors to suppress substance P release in the spinal cord, explaining why opioids are ineffective for neuropathic pain while still working for inflammatory pain.
Complete loss of inhibitionThe μ-opioid agonist DAMGO completely lost its ability to suppress substance P release after nerve injury — yet the same inhibition worked perfectly in inflammatory pain and normal animals, pinpointing where the opioid system breaks down.
What the researchers found
Nerve injury completely abolished the ability of μ-opioid receptors to inhibit substance P release from pain-sensing nerve fibers in the spinal cord of rats — explaining why opioids work poorly for neuropathic pain. In contrast, this opioid-mediated inhibition of substance P release remained intact in rats with inflammatory pain and in untreated rats. The loss of opioid control was not caused by fewer opioid receptors on nerve fibers — their numbers remained unchanged. Instead, the opioid receptors appeared to lose their ability to signal properly after nerve injury, even though they were still physically present.
Why it matters
It's a well-known clinical problem that opioids are much less effective for neuropathic pain (from nerve damage) than for inflammatory pain. This study provides a molecular explanation: nerve injury disrupts the opioid receptor's ability to suppress the release of substance P — a key pain-transmitting neuropeptide — in the spinal cord. Understanding this mechanism could lead to strategies to restore opioid sensitivity in neuropathic pain or to develop alternative approaches that bypass this broken signaling pathway.
The numbers in context
Complete loss of DAMGO (μ-opioid agonist) inhibition of SP release in CCI rats · Normal inhibition preserved in CFA inflammatory pain · μ-opioid receptor expression unchanged on primary afferents
How the study worked
Researchers used rats with chronic constriction injury (CCI) of the sciatic nerve as a neuropathic pain model and complete Freund's adjuvant (CFA) injection as an inflammatory pain model. Substance P release in the spinal cord was measured indirectly by tracking NK1 receptor internalization — when substance P is released, it binds NK1 receptors, which are then pulled inside the cell. The μ-opioid agonist DAMGO was tested for its ability to inhibit substance P release in spinal cord slices. Opioid receptor expression was assessed by immunofluorescence colocalization with substance P in dorsal root ganglion neurons.
Who was studied
Rats with chronic constriction nerve injury (neuropathic pain), complete Freund's adjuvant inflammation (inflammatory pain), and sham-operated or naïve controls
What this study cannot tell us
This is a rat study using an indirect measure of substance P release (NK1 receptor internalization). The CCI model, while well-established, may not perfectly replicate all forms of human neuropathic pain. The study demonstrates loss of opioid receptor signaling but does not fully elucidate the specific signaling mechanisms that are disrupted. The findings are specific to μ-opioid receptors and substance P — other opioid receptors and neurotransmitter systems may be affected differently.
How to read the evidence
This is a mechanistic animal study using well-established pain models and a validated indirect measure of substance P release. The clear dissociation between neuropathic and inflammatory pain provides strong mechanistic insight. However, translation to human pain physiology is uncertain.
When this study was published
Published in 2014, this study established an important mechanistic finding that remains widely cited in pain research. The concept of nerve injury-induced opioid resistance at the neuropeptide release level continues to inform neuropathic pain drug development.
The bigger picture
The opioid crisis has highlighted the need for better pain treatments, and the poor efficacy of opioids for neuropathic pain is both clinically frustrating and scientifically important. This study reveals that the problem isn't too few opioid receptors but broken receptor signaling — a more subtle and potentially fixable defect. Understanding exactly which signaling steps fail after nerve injury could lead to drugs that restore opioid receptor function or bypass the broken pathway entirely. This is particularly important as the field moves toward mechanism-based pain treatment rather than one-size-fits-all approaches.
Questions still open
- Which specific downstream signaling mechanisms of the μ-opioid receptor are disrupted by nerve injury, and can they be restored pharmacologically?
- Does this loss of opioid control over substance P release develop gradually after nerve injury, and is there a therapeutic window to prevent it?
- Could combining opioids with drugs that restore their signaling capacity improve neuropathic pain treatment without increasing opioid doses?
Common questions
Why don't opioids work well for nerve pain?
What is substance P and how does it relate to pain?
Read the original research
μ-Opioid receptor inhibition of substance P release from primary afferents disappears in neuropathic pain but not inflammatory pain.
Neuroscience, 267, 67-82
Citation
Chen, W; McRoberts, J A; Marvizón, J C G. (2014). μ-Opioid receptor inhibition of substance P release from primary afferents disappears in neuropathic pain but not inflammatory pain.. Neuroscience, 267, 67-82. https://doi.org/10.1016/j.neuroscience.2014.02.023